Structure Therapeutics (GPCR) CTO awarded options and 32,526 RSUs

Rhea-AI Filing Summary

Structure Therapeutics Inc. chief technology officer Yingli Ma reported equity compensation grants rather than market trades. Ma received an option to buy 40,278 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036, and 32,526 restricted stock units representing Ordinary Shares. The RSUs vest in four annual installments starting March 1, 2026, while the option vests 25% on March 1, 2027, with the remainder vesting monthly over three years. After the RSU grant, Ma directly holds 139,917 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.

Insights

Equity compensation analyst

Routine equity awards increase CTO’s share exposure without open-market trades.

The filing shows Yingli Ma, chief technology officer of Structure Therapeutics Inc., receiving an option for 40,278 Ordinary Shares at an exercise price of $16.82 and 32,526 RSUs, both as compensation grants rather than purchases.

The RSUs vest 1/4 annually from March 1, 2026, and the option vests over four years starting March 1, 2027. This back-loaded schedule is designed to promote retention and align incentives with long-term share performance.

Following the RSU grant, Ma directly holds 139,917 Ordinary Shares. The absence of sales and the use of multi-year vesting indicate standard executive equity planning rather than a signal about near-term share valuation.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ma Yingli

Role CHIEF TECHNOLOGY OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	40,278	$0.00	--
Grant/Award	Ordinary Shares	32,526	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 40,278 shares (Direct); Ordinary Shares — 139,917 shares (Direct)

Footnotes (1)

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ma Yingli

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNOLOGY OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/19/2026		A(2)		32,526	A	$0	139,917	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$16.82(3)	03/19/2026		A		40,278		(4)	03/18/2036	Ordinary Shares(1)	40,278	$0	40,278	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates.

3. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

4. 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Jun Yoon, Attorney-in-Fact	03/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did GPCR executive Yingli Ma receive in this Form 4 filing?

Yingli Ma received an employee stock option for 40,278 Ordinary Shares at an exercise price of $16.82 and 32,526 restricted stock units. Both awards are equity compensation grants, not open-market purchases, and increase her potential ownership in Structure Therapeutics Inc.

How do the new equity awards for GPCR CTO Yingli Ma vest?

The 32,526 RSUs vest 1/4 annually on each anniversary of March 1, 2026, subject to continued service. The option vests 1/4 on March 1, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, also conditioned on ongoing service.

Did Yingli Ma buy or sell Structure Therapeutics (GPCR) shares in this Form 4?

No open-market buys or sells occurred. The Form 4 reports two “A” code transactions, both classified as grant or award acquisitions: an employee stock option and RSU grant. These are compensation awards rather than discretionary trading in GPCR shares.

What is Yingli Ma’s direct shareholding in Structure Therapeutics after these grants?

After the RSU grant, Yingli Ma directly holds 139,917 Ordinary Shares of Structure Therapeutics Inc. This total reflects the non-derivative holding reported in the filing and shows her ongoing equity exposure as chief technology officer.

How are Structure Therapeutics Ordinary Shares related to its ADSs mentioned in the Form 4?

The filing notes that Ordinary Shares may be represented by American Depositary Shares. Each ADS represents three Ordinary Shares of Structure Therapeutics Inc., providing investors a way to trade the company’s equity through ADSs instead of the underlying Ordinary Shares.

When do the new options granted to GPCR CTO Yingli Ma expire?

The employee stock option granted to Yingli Ma expires on March 18, 2036. The exercise price per Ordinary Share is based on the fair market value on the grant date, determined from the trading price of the company’s American Depositary Shares.